MedTrace Logo

Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders

NCT04370028 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2583

Last updated 2021-03-10

Study results available
· View outcomes & findings →

Summary

An open-label, prospective, observational, multicenter study. The study enrolls adult outpatients with CCI from 8 federal districts of the Russian Federation.

Conditions

  • Chronic Cerebral Ischemia

Interventions

DRUG

Divaza

Oral administration.

Sponsors & Collaborators

  • Materia Medica Holding

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-01-31
Completion
2017-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04370028 on ClinicalTrials.gov